Defining and Modulating BRCAness to Improve the Precision of Prostate Cancer Therapy
Abstract
This proposal is focused on exploiting a specific subtype of metastatic CRPC, termed Homology Directed DNA Repair Deficient (HDR-D) prostate cancer (PC) to enhance treatment outcomes, reduce morbidity and improve survival. HDR-D represents at least 20% of metastatic PC and is most commonly identified through the genomic analysis of biopsies from metastatic tumors and identifying mutations in BRCA1, BRCA2 and related genes.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2022
- Accession Number
- AD1194712
Entities
People
- Peter S Nelson
Organizations
- Fred Hutchinson Cancer Center